LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aktien・Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

19.39 -3.72

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

19.3

Max

20.36

Schlüsselkennzahlen
By Trading Economics
Einkommen	25M -43M
Verkäufe	-3.6M 65M
EPS	-0.48
Gewinnspanne	-65.788
Angestellte	298
EBITDA	-16M -31M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+97.28% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	3. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	42M 1.9B
Vorheriger Eröffnungskurs	23.11
Vorheriger Schlusskurs	19.39

Nachrichtenstimmung

By Acuity

100%

320 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

9.91 / 14.15 Unterstützung & Widerstand

Syndax Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

17. Mai 2026, 23:53 UTC

Akquisitionen, Fusionen, Übernahmen

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15. Mai 2026, 22:47 UTC

Heiße Aktien

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15. Mai 2026, 22:16 UTC

Akquisitionen, Fusionen, Übernahmen

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15. Mai 2026, 22:00 UTC

Wichtige Markttreiber

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15. Mai 2026, 18:09 UTC

Wichtige Markttreiber

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17. Mai 2026, 23:50 UTC

Market Talk

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17. Mai 2026, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

17. Mai 2026, 23:43 UTC

Market Talk

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17. Mai 2026, 23:36 UTC

Market Talk

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17. Mai 2026, 23:07 UTC

Akquisitionen, Fusionen, Übernahmen

UOB: Transactions Part of Group's Capital Reallocation Strategy

17. Mai 2026, 23:06 UTC

Akquisitionen, Fusionen, Übernahmen

UOB: Share Sale Agreements Entered With Singland Properties

17. Mai 2026, 23:05 UTC

Akquisitionen, Fusionen, Übernahmen

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17. Mai 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Prudential PLC to Fund Stake Acquisition via Internal Resources

17. Mai 2026, 22:31 UTC

Akquisitionen, Fusionen, Übernahmen

Prudential PLC to Acquire Stake for $389 Million

17. Mai 2026, 22:30 UTC

Akquisitionen, Fusionen, Übernahmen

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16. Mai 2026, 16:27 UTC

Akquisitionen, Fusionen, Übernahmen

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16. Mai 2026, 15:26 UTC

Akquisitionen, Fusionen, Übernahmen

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16. Mai 2026, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 22:17 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15. Mai 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15. Mai 2026, 21:30 UTC

Akquisitionen, Fusionen, Übernahmen

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15. Mai 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15. Mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15. Mai 2026, 20:19 UTC

Heiße Aktien

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15. Mai 2026, 19:41 UTC

Akquisitionen, Fusionen, Übernahmen

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15. Mai 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15. Mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15. Mai 2026, 18:35 UTC

Ergebnisse

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Peer-Vergleich

Kursveränderung

Syndax Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

97.28% Vorteil

12-Monats-Prognose

Durchschnitt 39.91 USD 97.28%

Hoch 57 USD

Tief 29 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Syndax Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Syndax Pharmaceuticals Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

9.91 / 14.15Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Stimmung

By Acuity

320 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.